Skip to main content

Table 1 Baseline characteristics

From: Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis

Variable

Mean ± SD

Age (years)

62.0 ± 12.3

Sex (male/female)

12/8

Primary disease

 Chronic glomerulonephritis, n (%)

7 (35.0)

 Diabetic nephropathy, n (%)

5 (25.0)

 Nephrosclerosis, n (%)

3 (15.0)

 Unknown, n (%)

5 (25.0)

Duration of hemodialysis (years)

7.8 ± 9.6